Inactive Instrument

Highlights Kalytera Therapeutics Inc Toronto S.E.

Equities

CA48349P1036

Highlights

Unlock all the news: Be the first to know and act before the market!

Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107	21-08-18	MT
Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107	21-07-26	CI
Reverse Split: 1 of 20	21-07-22	FA
Claritas Pharmaceuticals : Reports Additional Data in Animal Model of Pulmonary Arterial Hypertension Treatment, R-107	21-07-21	MT
Claritas Pharmaceuticals, Inc. Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease	21-07-21	CI
Claritas Pharmaceuticals : 1-For-20 Share Consolidation Effective July 23	21-07-20	MT
Claritas Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-28	CI
Claritas Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-30	CI
Claritas Pharmaceuticals : In Agreement with CMAX Clinical Research for Phase 1 Clinical Study of Nitric Oxide-Releasing Drug, R-107	21-04-21	MT
Claritas Pharmaceuticals, Inc. Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107	21-04-21	CI
Claritas Pharmaceuticals : Announces Letter of Intent to Acquire Worldwide Rights to Develop R-107 Drug Compound	21-04-14	MT
Claritas Pharmaceuticals, Inc. entered into a binding Letter of Intent to acquire Exclusive Worldwide Rights of R-107 from Salzman Group Israel, Salzman Group Pty. Ltd. and Salzman Group, Inc. for $20.1 million.	21-04-13	CI
Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients	21-04-08	CI
Claritas Pharmaceuticals, Inc. Announces Completion of IND-Enabling In Vitro Genotoxicity Studies with R-107	21-04-01	CI
Claritas Pharmaceuticals, Inc. Announces Completion of Canine Toxicology Studies	21-03-17	CI
Claritas Pharmaceuticals, Inc. Announces Completion of IND-Enabling Rodent Toxicology Studies with R-107	21-03-12	CI
Claritas (Formerly Kalytera Therapeutics) Announces Additional Program to Reduce the Rate and Spread of Covid-19 with Prophylactic R-107 Nasal Spray Designed	21-03-04	CI
Claritas to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant Covid-19, Influenza, and Other Viral Infections	21-03-03	CI
Claritas (Formerly Kalytera Therapeutics) Cites Data by Massachusetts General Hospital and Others Demonstrating the Effectiveness of Nitric Oxide as a Potential Therapy for COVID-19 Infection and Validating the Potential of R-107 in this Indication	21-03-02	CI
Claritas Pharmaceuticals to Focus on Development of R-107 as A Therapy for Vaccine-Resistant Covid-19, Influenza, and Other Viral Infections	21-03-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kalytera Therapeutics Inc Toronto S.E.

Equities

CA48349P1036

Highlights

Filters